Geroscience & senolytics

Geroscience targets the shared molecular and cellular hallmarks of aging that underlie most chronic age-related diseases, rather than treating each disease separately. Its most clinically advanced arm is senolytics — small molecules or biologics that selectively clear senescent “zombie” cells, which stop dividing but resist apoptosis and instead secrete a toxic inflammatory cocktail (the senescence-associated secretory phenotype, or SASP) that drives chronic low-grade inflammation and drags neighboring healthy cells into senescence. Unity Biotechnology’s lead senolytic, UBX1325, a Bcl-xL inhibitor delivered locally into the eye, has produced 36-week clinical results and a publication in NEJM Evidence supporting long-term vision improvement in diabetic macular edema. In a parallel clinical program, Mayo Clinic researchers ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring a reduction in senescent-cell markers in treated patients. Rubedo Life Sciences has reported positive preliminary Phase 1 results for RLS-1496, a topical GPX4-modulating senolytic for plaque psoriasis, atopic dermatitis and skin aging, identified through its AI-driven ALEMBIC platform. Altos Labs, launched around 2022 with roughly $3 billion in funding, is pursuing a parallel strategy — partial cellular reprogramming to reverse a cell’s biological age without erasing its identity — rather than clearing senescent cells outright.

The key directions of geroscience and senolytics are:

1. Senolytics: small molecules or peptides that selectively trigger apoptosis in senescent cells by disabling their survival pathways (SCAP networks), such as Bcl-2/Bcl-xL inhibition or FOXO4-p53 disruption.
2. Senomorphics: compounds — such as mTOR inhibitors (rapamycin analogs) and metformin — that don’t kill senescent cells but suppress their toxic SASP secretion.
3. Cellular rejuvenation: partial epigenetic reprogramming with Yamanaka factors to roll back a cell’s biological age while preserving its cell-type identity.
4. Senescence biomarking: biomarker platforms (SA-β-gal activity, single-cell RNA-seq, SASP cytokine panels) used to identify senescent cells and measure how effectively a therapy clears them.

Sectoral value chain#

[Aging-Marker Identification] ──> [Senolytic Candidate Screening] ──> [Preclinical Testing (In Vivo)]
                  │                                 │                              │
        (SASP profiling, biomarkers)        (Compound libraries, HTS)    (Aged mouse models)
                                                                                    │
[Clinical Release (GMP)] <─── [Preclinical Synthesis & Purification (HPLC)] <──────┘

Value chain levels#

Cross-cutting technologies of the sector:

• SA-β-gal detection: the classic senescent-cell biomarker — enlarged lysosomes in senescent cells sharply raise beta-galactosidase activity at pH 6.0, letting researchers quantify how well a therapy clears zombie cells from tissue.
• Bcl-2/Bcl-xL inhibition: drugs (e.g., navitoclax, UBX1325) that block the anti-apoptotic Bcl-2-family proteins senescent cells rely on for survival, pushing the cell into programmed apoptosis.
• FOXO4-DRI peptide design: a synthetic peptide that disrupts the FOXO4-p53 interaction in senescent cells, releasing p53 to trigger apoptosis while sparing healthy dividing cells.

Modern geroprotector production and validation rests on the following technology stack:

1. Solid-phase peptide synthesis (SPPS):
   • Peptide senolytics like FOXO4-DRI are built stepwise on a solid resin using Fmoc-protected amino acids; substituting standard L-amino acids with mirror-image D-amino acids (retro-inverso peptides) makes them highly resistant to proteolytic degradation in blood.
2. Single-cell RNA sequencing (scRNA-seq):
   • Because senescent cells make up under roughly 1-5% of the total cell pool in aged tissue, bulk tissue sequencing can’t detect their signal; scRNA-seq profiles the RNA expression of thousands of individual cells to map specific SCAP-network and SASP-cytokine markers.
3. Ultra-high-performance liquid chromatography (UPLC-MS/MS):
   • Used to quantify SASP biomarkers (IL-6, IL-1, MCP-1 and related inflammatory proteins) in patient serum before and after senolytic therapy, assessing systemic anti-inflammatory and rejuvenating effect.